Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference, occurring October 3-4, 2022.
The presentation will be available for on-demand viewing using the virtual conference link beginning October 3, 2022 at 4:00 PM EST and will be archived for 120 days: https://wsw.com/webcast/chard14/xcur/1943406
Exicure will be taking 1×1 investor meetings with registered conference attendees.
About Exicure
Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening. For further information, see www.exicuretx.com.
Contacts
Media:
Karen Sharma
MacDougall
781-235-3060
[email protected]
